(a) In addition to any other information required by federal law, the commission shall include the following information in the annual report regarding the Medicaid Drug Utilization Review Program:
(1) a detailed description of the program’s activities; and
(2) estimates of cost savings anticipated to result from the program’s performance of prospective and retrospective drug use reviews.
(b) The cost-saving estimates for prospective drug use reviews under Subsection (a) must include savings attributed to drug use reviews performed through the vendor drug program’s electronic claims processing system and clinical edits screened through the prior authorization system implemented under Subchapter F.

(c) The commission shall post the annual report regarding the Medicaid Drug Utilization Review Program on the commission’s Internet website.

Text of section effective on April 01, 2025